GLPG 0555

Drug Profile

GLPG 0555

Alternative Names: GLPG 555; GLPG0555

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Galapagos NV
  • Developer Galapagos NV; GlaxoSmithKline
  • Class Disease-modifying antirheumatics; Small molecules
  • Mechanism of Action Protein kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Osteoarthritis(In volunteers) in Belgium (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Osteoarthritis(In volunteers) in Belgium (PO, Liquid)
  • 21 Feb 2012 GLPG 0555 licensed to GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top